title: [Reasons for the introduction of darunavir in the antirretroviral treatment in HIV-infected patients].
abstract: BACKGROUND
  In 2009 a deep change in ARV treatment took place in Spain with the introduction of new ARV drugs. The principal objective of the study was to determine the clinical situation of the patients in which DRV/r was introduced in the ARV therapy.
  
  
  METHODS
  Observational, cross sectional and multicentre study in which 91 reference hospitals participated. Patient's enrollment was carried out between 2008 and 2009. Data were collected retrospectively considering standard clinical practice.
  
  
  RESULTS
  719 medical records were reviewed. Patients had a different clinical situation compared to nowadays with predominance of multiresistant virus which leaded to virologic failure. The principal reason for introducing DRV/r in the ARV regimen was the virologic failure (54.2%).
  
  
  CONCLUSIONS
  Considering this situation, DRV/r became a therapeutic option which represented a change in the ARV paradigm in that period.
authors.affiliation: Servicio de Medicina Interna, Hospital Sant Pau i Santa Tecla Tarragona, Spain.
authors.forename: Enric
authors.initials: E
authors.lastname: Pedrol
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: López-Bernaldo
authors.forename: Sheila
authors.initials: S
authors.lastname: Ruiz
authors.forename: Henar
authors.initials: H
authors.lastname: Hevia
authors.forename: Francisco
authors.initials: F
authors.lastname: Ledesma
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods* / Q000706:statistics & numerical data / Q000639:trends; D003430:Cross-Sectional Studies; D000069454:Darunavir; D024882:Drug Resistance, Viral; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012737:Sex Factors; D012959:Socioeconomic Factors; D013030:Spain; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D000069454:Darunavir